Literature DB >> 19142590

Cholangiocarcinoma: expanding the spectrum of risk factors.

Diaa H Elfaki1, Andrea A Gossard, Keith D Lindor.   

Abstract

INTRODUCTION: Cholangiocarcinoma (CCA) is an epithelial cancer originating from the bile ducts with features of cholangiocyte differentiation. The global incidence of this rare disease is on the rise, and it is the second most common primary hepatobiliary malignancy. We reviewed risk factors for cholangiocarcinoma development and also described potential screening strategies for this malignancy. We also report two cases in which CCA developed in patients without previously determined risk factors known for CCA. DISCUSSION: The first case is a patient with longstanding secondary sclerosing cholangitis (SSC), and the second is a patient with autoimmune hepatitis (AIH). These two cases may indicate a possible association between SSC and AIH with CCA, thus, expanding the spectrum of risk factors of CCA.

Entities:  

Mesh:

Year:  2009        PMID: 19142590     DOI: 10.1007/s12029-008-9040-0

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  19 in total

Review 1.  Biliary tract cancers.

Authors:  P C de Groen; G J Gores; N F LaRusso; L L Gunderson; D M Nagorney
Journal:  N Engl J Med       Date:  1999-10-28       Impact factor: 91.245

Review 2.  Autoimmune hepatitis.

Authors:  Edward L Krawitt
Journal:  N Engl J Med       Date:  2006-01-05       Impact factor: 91.245

3.  Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis.

Authors:  Phunchai Charatcharoenwitthaya; Felicity B Enders; Kevin C Halling; Keith D Lindor
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

4.  Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.

Authors:  Antonio Jimeno; Belen Rubio-Viqueira; Maria L Amador; Darin Oppenheimer; Nadia Bouraoud; Peter Kulesza; Valeria Sebastiani; Anirban Maitra; Manuel Hidalgo
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

5.  Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis.

Authors:  Andrea A Gossard; Paul Angulo; Keith D Lindor
Journal:  Am J Gastroenterol       Date:  2005-06       Impact factor: 10.864

6.  Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.

Authors:  Marcus Wiedmann; Jürgen Feisthammel; Thilo Blüthner; Andrea Tannapfel; Thomas Kamenz; Annett Kluge; Joachim Mössner; Karel Caca
Journal:  Anticancer Drugs       Date:  2006-08       Impact factor: 2.248

7.  Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor.

Authors:  K Date; K Matsumoto; K Kuba; H Shimura; M Tanaka; T Nakamura
Journal:  Oncogene       Date:  1998-12-10       Impact factor: 9.867

8.  The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells.

Authors:  Tong Wu; Jing Leng; Chang Han; Anthony Jake Demetris
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

Review 9.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

10.  The assessment of biliary CA 125, CA 19-9 and CEA in diagnosing cholangiocarcinoma--the influence of sampling time and hepatolithiasis.

Authors:  Chiung-Yu Chen; Shu-Chu Shiesh; Hui-Chen Tsao; Xi-Zhang Lin
Journal:  Hepatogastroenterology       Date:  2002 May-Jun
View more
  4 in total

1.  Endoscopic ultrasound with biopsy of omental mass for cholangiocarcinoma diagnosis in cirrhosis.

Authors:  Nathaniel S Rial; Kevin B Gilchrist; Jeff T Henderson; Achyut K Bhattacharyya; Thomas D Boyer; Abdul Nadir; John T Cunningham
Journal:  World J Gastrointest Endosc       Date:  2011-06-16

2.  Use of endoscopic ultrasound for diagnosis of cholangiocarcinoma in auto-immune hepatitis.

Authors:  Nathaniel S Rial; Jeff T Henderson; Achyut K Bhattacharyya; Abdul Nadir; John T Cunningham
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

3.  Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review.

Authors:  Audra N Boscoe; Catherine Rolland; Robin Kate Kelley
Journal:  J Gastrointest Oncol       Date:  2019-08

4.  Autoimmune Hepatitis: A Risk Factor for Cholangiocarcinoma.

Authors:  Rajat Garg; Uqba Khan; Ahmed AlRajjal; Zyad Kafri
Journal:  Case Rep Gastroenterol       Date:  2017-11-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.